Microglial Activation in Inflammatory Bowel Disease

Inflammatory Bowel Diseases Clinical Trial

Official title: Naturalistic Monitoring of Microglial Activation in Inflammatory Bowel Disease

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to monitor microglial activation in participants with inflammatory bowel disease (IBD) and investigate the relationship that exists between these patients and their risk of acquiring major depressive episodes (MDE). Patients with both IBD and MDE will be subsequently approached to participate in the study.

Clinical Trial Description

Detailed Description:

Participants may undergo up to 3 PET Scans : [18F]FEPPA PET (for TSPO) before and 3 to 6 months later and [11C]SL25.1188 PET (for MAO-B) as well as 1 MRI scan.

The primary hypothesis is that :

1. The neuroinflammation (TSPO VT) will be increased in PFC, ACC, and insula regions in those with inflammatory bowel disease (IBD) patients compared to healthy people.

2. The neuroinflammation (TSPO VT) in PFC, ACC, and insula regions will be reduced after treatment for IBD.

The Secondary Hypothesis:

1. Elevations in neuroinflammation (TSPO VT) will be similar in those with ulcerative colitis and Crohn's disease.

2. Neuroinflammation (TSPO VT) will be greater in IBD with depression than in depression without IBD.

3. Biologics (TNFalpha antibody treatments), and fecal transplantation will be associated with greater reduction in neuroinflammation in brain than Sulfasalazine/5-Aminosalicylates.

4. MAO-B VT will be elevated in in the PFC, ACC, and insula in IBD compared to healthy controls.

There will be no alterations to standard care of patients due to participation in the study. ;

Related Conditions & MeSH terms

• Inflammatory Bowel Diseases
• Intestinal Diseases
• Major Depressive Episode

• NCT number: NCT03487926
• Study type: Observational
• Source: Centre for Addiction and Mental Health
• Status: Active, not recruiting
• Start date: September 14, 2022
• Completion date: December 31, 2024